Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
HPG-1860 in Metabolic Dysfunction Associated Steatohepatitis: NCT05338034 Clinical Landscape Report 2026
16 October 2026
NCT05338034 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Mitapivat in Hemoglobin SC Disease: LBCTR2022034916 Clinical Landscape Report 2026
16 October 2026
LBCTR2022034916 clinical landscape for Hemoglobin SC Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxycarbamide in Anemia, Sickle Cell: CTRI/2022/04/042006 Clinical Landscape Report 2026
16 October 2026
CTRI/2022/04/042006 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Heptex in Metabolic Dysfunction Associated Steatohepatitis: NCT05343780 Clinical Landscape Report 2026
16 October 2026
NCT05343780 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
XFB-19 in Idiopathic Pulmonary Fibrosis: NCT05361733 Clinical Landscape Report 2026
16 October 2026
NCT05361733 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Celecoxib/Ciprofloxacin in Amyotrophic Lateral Sclerosis: NCT05357950 Clinical Landscape Report 2026
16 October 2026
NCT05357950 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AMB-051 in Idiopathic Pulmonary Fibrosis: NCT05349760 Clinical Landscape Report 2026
16 October 2026
NCT05349760 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Utreloxastat in Amyotrophic Lateral Sclerosis: NCT05349721 Clinical Landscape Report 2026
16 October 2026
NCT05349721 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Autologous CD34+ HSC cells(Boston Children's Hospital) in Anemia, Sickle Cell: NCT05353647 Clinical Landscape Report 2026
16 October 2026
NCT05353647 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Inclacumab in Vaso-occlusive crisis: NCT05348915 Clinical Landscape Report 2026
16 October 2026
NCT05348915 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sirolimus in Beta-Thalassemia: NCT05357482 Clinical Landscape Report 2026
16 October 2026
NCT05357482 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cotadutide in Metabolic Dysfunction Associated Steatohepatitis: NCT05364931 Clinical Landscape Report 2026
16 October 2026
NCT05364931 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…